Trials / Completed
CompletedNCT05986682
Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (actual)
- Sponsor
- Duke University · Academic / Other
- Sex
- All
- Age
- 18 Years – 89 Years
- Healthy volunteers
- —
Summary
The purpose of this study is to describe the real-world use of Belantamab Mafodotin - blmf (BLENREP) and associated patterns of care, including dosing and dose modification, eye care specialist visits, associated healthcare utilization, and clinical outcomes in patients with relapsed and/or refractory multiple myeloma (RRMM) seen in the Duke Cancer Institute (DCI) clinics.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Blenrep | Belantamab Mafodotin - blmf (BLENREP) given for the treatment of relapsed and/or refractory multiple myeloma. |
Timeline
- Start date
- 2023-09-18
- Primary completion
- 2023-11-07
- Completion
- 2023-11-07
- First posted
- 2023-08-14
- Last updated
- 2025-02-03
- Results posted
- 2025-02-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05986682. Inclusion in this directory is not an endorsement.